AVBPArriVent BioPharma, Inc. Common Stock

AVBP Stock Price, Valuation & Chart | ArriVent BioPharma, Inc. Common Stock

Compare

$30.510+0.36 (+1.19%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AVBP intrinsic value AVBP calculated fair value vs price

Overview Financials Dividends Ratios

AVBP Historical price chart

AVBP Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.42B

PE Ratio-8.79

EPS-3.47

Trading Volume423.75K

Today's High/Low30.79/29.6

Dividend Yield0.00

52 Week High/Low35.83/17.0

Shares Outstanding46.57M

AVBP Financial Statement

AVBP Analyst ratings

AVBP Analysis & performance metrics

AVBP Company profile

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the…

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops…

AVBP Management team

Name

Position

Stuart Lutzker M.D., Ph.D.CTO

Co-Founder, President of Research & Development and Director

Zhengbin Yao Ph.D.CEO

Co-Founder, Chairman, President & Chief Executive Officer

Yang Wang Ph.D.CTO

Chief Technology Officer

Robin LaChapelle M.A.COO

Co-Founder & Chief Operating Officer

Winston Kung M.B.A.CFO

Chief Financial Officer & Treasurer

James Paul Kastenmayer J.D., Ph.D.

General Counsel & Secretary

Meghna Chowdary

Senior Vice President of Commercial Strategy

Name

Position

Stuart Lutzker M.D., Ph.D.CTO

Co-Founder, President of Research & Development and Director

Zhengbin Yao Ph.D.CEO

Co-Founder, Chairman, President & Chief Executive Officer

Yang Wang Ph.D.CTO

Chief Technology Officer

Robin LaChapelle M.A.COO

Co-Founder & Chief Operating Officer

Winston Kung M.B.A.CFO

Chief Financial Officer & Treasurer

James Paul Kastenmayer J.D., Ph.D.

General Counsel & Secretary

Meghna Chowdary

Senior Vice President of Commercial Strategy

Management Team

Stuart Lutzker M.D., Ph.D.CTO

Co-Founder, President of Research & Development and Director

Zhengbin Yao Ph.D.CEO

Co-Founder, Chairman, President & Chief Executive Officer

Yang Wang Ph.D.CTO

Chief Technology Officer

Robin LaChapelle M.A.COO

Co-Founder & Chief Operating Officer

Winston Kung M.B.A.CFO

Chief Financial Officer & Treasurer

James Paul Kastenmayer J.D., Ph.D.

General Counsel & Secretary

Meghna Chowdary

Senior Vice President of Commercial Strategy

Management

Stuart Lutzker M.D., Ph.D.CTO

Co-Founder, President of Research & Development and Director

Zhengbin Yao Ph.D.CEO

Co-Founder, Chairman, President & Chief Executive Officer

Yang Wang Ph.D.CTO

Chief Technology Officer

Robin LaChapelle M.A.COO

Co-Founder & Chief Operating Officer

Winston Kung M.B.A.CFO

Chief Financial Officer & Treasurer

James Paul Kastenmayer J.D., Ph.D.

General Counsel & Secretary

Meghna Chowdary

Senior Vice President of Commercial Strategy

Total 7 executives

AVBP Frequently asked questions

What is ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Price?

Current stock price of ArriVent BioPharma, Inc. Common Stock (AVBP) stock is $30.510. The stock price is +1.19% higher in the session. The intraday range can be seen from this page. Volume of ArriVent BioPharma, Inc. Common Stock (AVBP) stock is 423.75K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the ArriVent BioPharma, Inc. Common Stock (AVBP) stock price going up or down today?

The stock price of ArriVent BioPharma, Inc. Common Stock (AVBP) can change with earnings, company news, and overall market sentiment. ArriVent BioPharma, Inc. Common Stock operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the ArriVent BioPharma, Inc. Common Stock stock expensive at its current price?

Whether ArriVent BioPharma, Inc. Common Stock looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AVBP on this page is -8.79. EPS on this page is -3.47. Compare those figures with peers and growth expectations before deciding if the current ArriVent BioPharma, Inc. Common Stock price is justified.

How has the stock price of ArriVent BioPharma, Inc. Common Stock (AVBP) performed historically?

Historical performance for ArriVent BioPharma, Inc. Common Stock (AVBP) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AVBP reacted to past earnings and market events.

Should I buy ArriVent BioPharma, Inc. Common Stock (AVBP) stock, at this price?

Buying ArriVent BioPharma, Inc. Common Stock (AVBP) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.